Think of it as radical bio-intelligence
We combine artificial intelligence with automation to conduct experimental biology at scale — testing thousands of compounds on hundreds of cellular disease models in parallel. Our embrace of systems biology and our commitment to an unbiased approach are leading to novel discoveries. With every experiment, our system gets smarter.
We’re using technology to accelerate every step in drug discovery.
In just a few years we’ve built the world’s largest dataset of biological images. Using the latest in artificial intelligence methods, we’re training our algorithms on this data to predict important properties of new medicines with the goal of discovering treatments for hundreds of diseases.
“Deep learning has recently proven capable of driving cars, beating the world champion of the game of Go, translating from one language to another and recognizing faces dramatically better than any previous efforts to date. Recursion is taking this success and applying it to millions of high-resolution cellular images, with a high potential to make biological discoveries with a medical impact and breadth never seen before.”
Recursion Scientific Advisor
Our investors
The latest news
Articles and Press Releases
07.10.18
AI/ML-based drugmaker gets FDA green light for Phase I study
Recursion plans to start study of machine learning-discovered drug REC-994 later this year, CEO says.
07.10.18
Veteran Biopharma Operations Leader Tina M. Larson to Join Recursion as Chief Operating Officer
Recursion adds industry leader in developing and manufacturing biopharmaceuticals
07.10.18
Recursion Receives FDA Clearance of Investigational New Drug Application to Initiate First Clinical Trial of REC-994 in Cerebral Cavernous Malformation
Up to 1.5 million individuals in the United States with CCM may be impacted
